Processa Completes Enrollment And Dosing Of 20 Patients For Planned Formal Interim Analysis In Ongoing Phase 2 Clinical Study Evaluating NGC-Cap In Patients With Breast Cancer; Interim Data To Be Reported In Q1

Benzinga · 01/05 14:18

Interim safety and efficacy data to be reported in Q1

VERO BEACH, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today reported that it completed the enrollment and dosing of the 20 patients required for the planned formal interim analysis in its ongoing Phase 2 clinical study evaluating NGC-Cap, Processa's proprietary combination treatment of PCS6422 and capecitabine, in patients with advanced or metastatic breast cancer.